Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 2,698 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Specimen #1 Clear all
Completed No phase listed Observational

Prematurity and Respiratory Outcomes Program (PROP)

NCT01435187
View directory record Official record
Conditions
Prematurity, Respiratory Disease
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
1 Day to 7 Days
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
13
States / cities
Oakland, California • San Francisco, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 17, 2026, 12:55 AM EDT
Completed Not applicable Interventional Results available

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

NCT02508116
View directory record Official record
Conditions
Acute Coronary Syndrome, Cardiovascular Diseases
Interventions
CYP2C19 genotyping
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 17, 2026, 12:55 AM EDT
Recruiting Not applicable Interventional

Yoga for Persistent Post-Surgical Pain (PPSP)

NCT06949007
View directory record Official record
Conditions
Persistent Post-surgical Pain
Interventions
Yoga, Chronic Pain Health Education
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Local Anesthesia and Pain Perception During an Amniocentesis

NCT00583011
View directory record Official record
Conditions
Pregnancy
Interventions
Local Anesthesia, Placebo Group
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 17, 2026, 12:55 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Social Engagement Strategies to Improve Medication Adherence

NCT03734887
View directory record Official record
Conditions
Diabetes, Atherosclerosis Cardiovascular Disease, Congestive Heart Failure, Poor Medication Adherence
Interventions
Social Network Feedback, Private Feedback
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 17, 2026, 12:55 AM EDT
Recruiting Early Phase 1 Interventional

Addictive Threshold of Nicotine

NCT06096714
View directory record Official record
Conditions
Smoking Addiction
Interventions
Nicotine, Saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
21 Years to 59 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Determine Racial and Gender Differences in Platelet Aggregation

NCT00233428
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Blood Draw
Procedure
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 17, 2026, 12:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study

NCT05055362
View directory record Official record
Conditions
Chronic Kidney Diseases, Overweight and Obesity
Interventions
Honey Spice Group
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 17, 2026, 12:55 AM EDT
Suspended Phase 1Phase 2 Interventional

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

NCT05861050
View directory record Official record
Conditions
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Glofitamab, Lenalidomide, Obinutuzumab, Positron Emission Tomography, Venetoclax
Procedure · Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Duarte, California • New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SCD-PROMIS: A Software Platform to Enhance Self-efficacy and Patient-provider Engagement for Patients With Sickle Cell Pain

NCT03006718
View directory record Official record
Conditions
Sickle Cell Disease, Anemia, Anemia, Hemolytic, Anemia, Sickle Cell, Hematologic Diseases
Interventions
PROMIS for Pain Management App
Other
Lead sponsor
Julia Finkel
Other
Eligibility
8 Years to 21 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 17, 2026, 12:55 AM EDT
Recruiting Phase 2 Interventional

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

NCT06492759
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Radiation Therapy, Pembrolizumab, Nab-paclitaxel, Paclitaxel, Carboplatin, Gemcitabine, Biopsy, Computed Tomography, Bone Scan, Biospecimen Collection, Medical Chart Review
Radiation · Biological · Drug + 2 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Withdrawn No phase listed Observational

Role of Chemokine and Chemokine Receptor in Psoriasis

NCT03302390
View directory record Official record
Conditions
Psoriasis
Interventions
Shave Biopsy of Psoriasis Lesion
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 17, 2026, 12:55 AM EDT
Recruiting Phase 3 Interventional

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

NCT04181060
View directory record Official record
Conditions
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
603
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 425 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

NCT04345913
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Eribulin Mesylate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
43
States / cities
Sacramento, California • Derby, Connecticut • Fairfield, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Not listed No phase listed Observational

Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension

NCT04489251
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Protein Elisa analysis, microRNA analysis, whole exome sequencing
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 17, 2026, 12:55 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

NCT03779854
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blasts Under 25 Percent of Bone Marrow Nucleated Cells, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Burkitt Leukemia, Chronic Monocytic Leukemia, Lymphoblastic Lymphoma, Mast Cell Leukemia, Myeloproliferative Neoplasm
Interventions
Total-Body Irradiation, Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Allogeneic Bone Marrow Transplantation, Tacrolimus, Methotrexate, Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation, Echocardiography, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
Radiation · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 26 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma

NCT00782756
View directory record Official record
Conditions
Brain Cancer, Malignant Glioma
Interventions
radiotherapy (RT) in combination with temozolomide and bevacizumab
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 17, 2026, 12:55 AM EDT
Completed Phase 1 Interventional Results available

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

NCT03801902
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy
Radiation · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
56
States / cities
Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Oct 17, 2026, 12:55 AM EDT
Completed Phase 2 Interventional Results available

Niclosamide for Mild to Moderate COVID-19

NCT04399356
View directory record Official record
Conditions
COVID-19
Interventions
Niclosamide, Placebo, Telehealth monitoring
Drug · Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 17, 2026, 12:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sex Differences in Gene Expression in Human Adipose Tissue

NCT00677651
View directory record Official record
Conditions
Healthy, Obesity
Interventions
Adipose Biopsy, Blood sample, CT Scan, DEXA
Procedure · Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
20 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2009 · Synced Oct 17, 2026, 12:55 AM EDT
Recruiting Not applicable Interventional

Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis

NCT06830265
View directory record Official record
Conditions
Prostate Cancer Screening
Interventions
Novel needle biopsy catheter (test)
Device
Lead sponsor
Uro-1 Medical
Industry
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Hardeeville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

NCT06917911
View directory record Official record
Conditions
Core Binding Factor Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Gemtuzumab Ozogamicin, Multigated Acquisition Scan, Venetoclax
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 59 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
70
States / cities
Birmingham, Alabama • La Jolla, California • Pembroke Pines, Florida + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

NCT04797767
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myeloid Neoplasm, Relapsed Acute Biphenotypic Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Mixed Phenotype Acute Leukemia, Relapsed Myeloid Neoplasm, Refractory Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myeloid Neoplasm, Recurrent Myeloid Sarcoma
Interventions
Cladribine, Cytarabine, Mitoxantrone, Recombinant Granulocyte Colony-Stimulating Factor, Venetoclax, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 17, 2026, 12:55 AM EDT
Terminated No phase listed Observational

Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases

NCT02688309
View directory record Official record
Conditions
Macular Edema, Fibrosis of the Retina
Interventions
Ozurdex, Surgery, Anterior Chamber (AC) Tap
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 17, 2026, 12:55 AM EDT